Importance A 2016 review for the US Preventive Services Task Force (USPSTF) found use
of statins for primary prevention of cardiovascular disease (CVD) was associated with …

Objective To assess the associations between statins and adverse events in primary
prevention of cardiovascular disease and to examine how the associations vary by type and …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well
tolerated, but associated with various statin-associated symptoms (SAS), including statin …

Importance Cardiovascular disease (CVD), the leading cause of mortality and morbidity in
the United States, may be potentially preventable with statin therapy. Objective To …

Alzheimer's disease (AD) is an age‐associated neurodegenerative disorder with
multifactorial etiology, intersecting genetic and environmental risk factors, and a lack of …

Background Findings from clinical trials of proprotein convertase subtilisin–kexin type 9
(PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density …

Statins are a family of drugs that are used for treating hyperlipidaemia with a recognized
capacity to prevent cardiovascular disease events. They inhibit β‐hydroxy β‐methylglutaryl …

HMG-CoA reductase inhibitors (statins) are a widely used class of drug, and like all
medications, have potential for adverse effects (AEs). Here we review the statin AE literature …

Presenilin mutations that alter γ-secretase activity cause familial Alzheimer's disease (AD),
whereas ApoE4, an apolipoprotein for cholesterol transport, predisposes to sporadic AD …